20 closest matches · ranked by relevance
Erythema Chronicum Migrans
Primary: Objective Sequelae and Post-treatment Subjective New or Increased Symptoms (NOIS)in Patients Treated for Erythema Migrans With Doxycycline for 10 or 15 Days. — 79; 85…
Erythema Migrans · Post-Lyme Disease Symptoms
Primary: Objective Lyme Disease Manifestations and Post-Lyme Disease Symptoms at 14 Days — 30; 27 participants
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
Erythema Migrans
Primary: Detection of Borrelia Burgdorferi Sensu Lato by Microscopy in Dark Field (Positive vs. Negative) — 102; 59 culture-positive skin samples
Lyme Disease
Primary: Detection of Borrelia Burgdorferi in Ticks After Xenodiagnosis Procedure — 1; 0; 418; 319 Ticks
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Erythema · Rosacea
Primary: Inter-rater Reliability of the Clinician Erythema Assessment (CEA) Scale — 0.908 Kendall's W
Post-Treatment Lyme Disease Syndrome
Primary: Horowitz Lyme-Multiple Systemic Infectious Disease Syndrome Questionnaire — 50.5; 44.8; 33.8; 25.6 score on a scale — p=0.07
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Primary Erythromelalgia · Inherited Erythromelalgia
Primary: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 — 0.24; 2.4 cooling uses/day
Fatigue · Quality of Life
Primary: Fatigue Severity Scale (FSS) — 4; 2 Participants
BRAF V600E Mutation
Primary: Number of Participants With Partial Response to Dabrafenib and Trametinib — 4 Participants
Neuroborreliosis, Borrelia Burgdorferi
Primary: Difference in Composite Clinical Score From Inclusion to Six Months After Ended Treatment — 6.4; 6.4 units on a scale
Erythropoietic Protoporphyria
Primary: Duration of Direct Sunlight Exposure Between 10:00 and 18:00 Hours on Days When no Pain Was Experienced (Pain Score of 0). — 69.4; 40.8 hours
Myocardiopathies · Ischemia, Myocardial · Arrythmia
Primary: MMP-2 — 173493.4; 139012.4 pg/ml
Migraine Disorder
Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) — 91 Participants
Platelet Aggregation, Spontaneous · Migraine With Aura · Patent Foramen Ovale
Primary: Change in Migraine Characteristics — 43; 2; 17 Participants
Migraine
Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days
Erythropoietic Protoporphyria
Primary: Time in Direct Sunlight Between 10:00-15:00 on Pain-free Days — 8.25; 0.75 Hours
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98